Press release
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
Treatment algorithm can assist clinicians in tailoring their care for patients with high-risk cutaneous squamous cell carcinoma (cSCC) based on individual
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nTreatment algorithm can assist clinicians in tailoring their care for patients with high-risk cutaneous squamous cell carcinoma (cSCC) based on individual patient’s unique tumor biology, while adhering to guideline recommendations\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results into clinical practice within National Comprehensive Cancer Network (NCCN) guideline recommendations.1 This framework for stratifying patients with advanced cSCC includes a treatment algorithm that demonstrates how use of DecisionDx-SCC test results can assist clinicians in identifying personalized, risk-aligned treatment pathway improvements for patients with high-risk cSCC, based on the patient’s tumor biology, which may help improve their disease outcome.\n\n\n“While current guidelines and staging frameworks for cSCC provide guidance for stratifying patients based on their risk of metastasis, the recommendations can be challenging to implement as they are based on a broad set of clinicopathologic risk factors,” said first author Gaurav Singh, M.D., M.P.H., F.A.A.D., board-certified dermatologist and fellowship-trained Mohs surgeon in Milwaukee. “The algorithm that we developed is not meant to challenge these established guidelines. Rather, it is designed to enhance existing risk-stratification approaches by integrating a patient’s tumor biology into the decision-making process through the use of DecisionDx-SCC test results and providing options for clinicians to consider when deciding future steps in the care of each patient.”\n\n\nThe DecisionDx-SCC test has been validated to independently identify cSCC patients who have tumors with high metastatic potential. In the study, three private-practice Mohs surgeons, who routinely use the test to risk-stratify their high-risk cSCC patients, merged their management approaches for three real-world, high-risk cSCC patients into a singular algorithm that provides a framework for incorporating each of the test’s three potential results into current NCCN guidelines. This algorithm ...